COMPASS Pathways Plc American Depository Shares (CMPS) is a publicly traded Healthcare sector company. As of May 21, 2026, CMPS trades at $11.00 with a market cap of $1.43B and a P/E ratio of -3.47. CMPS moved +8.04% today. Year to date, CMPS is +65.70%; over the trailing twelve months it is +135.28%. Its 52-week range spans $2.25 to $11.65. Analyst consensus is strong buy with an average price target of $23.50. Rallies surfaces CMPS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Compass Pathways Confirms Full Phase IIb Enrollment and Mid-2027 Cash Runway: Compass Pathways’s Q1 2026 earnings call reported full enrollment in its COMP360 Phase IIb psilocybin therapy trial and initiation of a pivotal Phase III study. The company confirmed a cash runway extending into mid-2027 after securing additional R&D funding.
| Metric | Value |
|---|---|
| Price | $11.00 |
| Market Cap | $1.43B |
| P/E Ratio | -3.47 |
| EPS | $-3.08 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.65 |
| 52-Week Low | $2.25 |
| Volume | 1.51K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-287.86M |
| Gross Margin | 0.00% |
12 analysts cover CMPS: 0 strong buy, 12 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $23.50.